integrin α5β1

Anti-Integrin α5β1 Antibody is an antibody targeting Integrin α5β1 and can be used for life science research.

α5β1integrin agonist-2 (Compound 2) is a highly selective agonist of the α5β1 integrin, with an EC50 of 45.98 nM. It enhances extracellular matrix adhesion and activates the Akt/ERK signaling pathways. This compound shows potential for research in ischemic stroke.

α5β1integrin-IN-1 (compound 65) is a potent and selective α5β1 integrin inhibitor with a pIC50 of 9.4. Its selectivity for α5β1 is over 10,000 times greater than for αVβ3 (pIC50 of 5.5). This compound reduces airway smooth muscle (ASM) tension by disrupting intercellular connections. In rodents, α5β1integrin-IN-1 demonstrates excellent inhalation pharmacokinetic properties and is applicable in asthma research.

α5β1 integrin agonist-1 is an α5β1 integrin agonist that selectively delivers 5-FU to tumour cells and induces tumour cell death.

αvβ5 integrin-IN-1, a potent and selective αvβ5 integrin inhibitor, exhibits a high inhibitory potency with a pIC50 value of 8.2.

K34c hydrochloride is an alpha5β1 integrin antagonist for glioblastoma study.

CLT-28643 is a potent and specific α5β1-Integrin inhibitor that prevents fibrosis in glaucoma filtration surgery (GFS), inhibits tumor growth and angiogenesis, suppresses fibrosis and inflammation in a bleomycin-induced lung fibrosis model, and improves insulin sensitivity and cardiac function in H9C2 cells from obese mice.

ATN-161 trifluoroacetate salt (ATN-161 TFA salt) is a novel integrin α5β1 antagonist that inhibits angiogenesis and growth of liver metastases and improves survival in a murine model.

ATN-161 is an integrin α5β1 binding peptide and antagonist that inhibits VEGF-induced hCECs migration and angiogenesis. ATN-161 also suppresses spike protein interaction with integrin α5β1 and may be employed against SARS-CoV-2 infection.

c (phg-isoDGR- (NMe) k) is a selective and effective α5β1-integrin ligand with IC50 of 2.9 nM.

c(phg-isoDGR-(NMe)k) TFA is a potent and selective α5β1-integrin ligand (IC50: 2.9 nM).

MK-0429 is an orally active, selective, and nonpeptide antagonist of αvβ3 integrin (IC50: 80 nM).

LT25 (compound 17) acts as an agonist for the α5β1 integrin, exhibiting an EC50 value of 9.9 nM.

Cilengitide (EMD 121974) is a potent integrin inhibitor for the αvβ3/5 receptor (IC50: 4.1/79 nM, in cell-free assays) with approximately 10-fold selectivity against gpIIbIIIa.

Echistatin TFA, the smallest active RGD protein from snake venoms, is a potent inhibitor of platelet aggregation, bone resorption in culture, and an antagonist of αIIbβ3, αvβ3, and α5β1[1][2][3][4].

THI0019 is a highly potent agonist of the integrin α4β1 (VLA-4) receptor, with an EC 50 range of 1-2 μM. It effectively promotes the adhesion of stem/progenitor cells. Furthermore, THI0019 successfully modulates adhesion processes mediated by α4β7, α5β1, and αLβ2 integrins.

K34C is a selective inhibitor of Integrin α5β1, which inhibits cell survival and migration, promotes apoptosis in U87MG cells, inhibits TGFβ-induced invasion, and reduces cell adhesion to fibronectin.

C(phg-isoDGR-(NMe)k) TFA is a selective and potent ligand for α5β1-integrin, exhibiting an IC50 of 2.9 nM [1].

RGD peptide (GRGDNP) TFA functions as an inhibitor of integrin-ligand interactions, competitively blocking α5β1's interaction with the extracellular matrix (ECM). It induces apoptosis by triggering conformational changes that facilitate pro-caspase-3 activation and autoprocessing. Furthermore, RGD peptide (GRGDNP) TFA is critical in regulating cell adhesion, migration, growth, and differentiation [1] [2] [3].

αvβ1 integrin-IN-2 (compound 32) is a potent inhibitor of ανβ1 and α5β1 integrins, exhibiting IC50 values of 0.9 nM and 33 nM, respectively. This compound also inhibits other integrins with IC50 values of 380 nM (ανβ3), 280 nM (ανβ5), 230 nM (ανβ6), and 87 nM (ανβ8), as determined by the SPRA assay [1].

Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide and synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin on Caco-2 cells [1].

Volociximab (M200) is an IgG4 monoclonal antibody targeting the α5β1 integrin , with antiangiogenic, antitumor and anticancer activity, inhibits the growth of rabbit VX2 tumors and is used to study solid tumors.

MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin, exhibiting significant anti-angiogenic activity. This compound is applicable in cancer research.

CT20p is an anticancer peptide derived from the hydrophobic terminal of BaxC. It exhibits a unique cytotoxic effect independent of the full-length Bax, targeting mitochondria to induce fusion-like aggregation and mitochondrial membrane hyperpolarization. CT20p reduces α5β1 integrin levels, inhibits F-actin polymerization, thus disrupting the cytoskeleton and preventing cell adhesion. CT20p is applicable in breast cancer research.